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Abstract
The primary goals of clinical research monitoring are to assure adequate
protection of the rights of human subjects, and the safety of all subjects involved in
clinical investigations or clinical trials, and the quality and integrity of the data generated
from clinical trials. Adequate monitoring of clinical trials can prevent the occurrence of
significant problems, which may affect the entire process of bringing a new drug to
market. The proper monitoring of clinical trials is a challenge. In spite of well established
regulations and guidance, there remain many monitoring related concerns in clinical trials
(e.g. protocol deviations and violations, IRB violations, improper adverse event
reporting, etc). The survey results indicate that clinical research coordinators believe that
there are concerns in the monitoring process, and that the quality of monitoring varies
from monitor to monitor. Results also suggest that some monitors are exceptional, where
as some monitors are abysmal.

v

Table of Contents

Dedication ........................................................................................................................... ii

Acknowledgments.............................................................................................................. iii

Abstract ............................................................................................................................... v

List of Tables ..................................................................................................................... ix

List of Figures .................................................................................................................... xi

Chapter 1: Introduction ....................................................................................................... 1

Chapter 2: Background ....................................................................................................... 5

Chapter 3: Thesis Statement ............................................................................................... 7

Purpose of the Study ...................................................................................................... 7

Research Questions ........................................................................................................ 7

Chapter 4: Research Design and Methodology .................................................................. 8

Target Population ........................................................................................................... 8

Sample Population ......................................................................................................... 8

vi

Selection of Sample Size for Survey ............................................................................. 8

Development of Survey Instrument or Questionnaire ................................................... 9

Human Subjects Protection ............................................................................................ 9

Method of Data Collection........................................................................................... 10

Chapter 5: Analysis and Presentation of Data .................................................................. 12

Overview of Demographics ......................................................................................... 12

Overview of Responses or Reflections based on Monitoring Practice Questions ....... 16

Summary of Results/Findings based on the Data Collected ........................................ 25

Chapter 6: Summary, Conclusion, and Inferences............................................................ 29

Major Concerns or Problems in the Monitoring Process ............................................. 31

Clinical Research Coordinators Perceptions about the Quality of Monitoring ........... 32

Reasons for Decreased Quality of Monitoring ............................................................ 32

How Can we Improve the Quality of Monitoring? ...................................................... 33

Conclusion ................................................................................................................... 34

vii

Limitations and Recommendations for Future Research ............................................. 36

References ......................................................................................................................... 37

Demographic Profile of Clinical Research Coordinators ................................................. 40

Presentation of Responses to Monitoring Practice Questions .......................................... 46

Appendix A: College of Health and Human Services Human Subjects Review
Committee Approval Letter .............................................................................................. 63

Appendix B: Survey Completion Request or Online Survey Consent Form or Email
Survey ............................................................................................................................... 64

Appendix C: Survey.......................................................................................................... 67

viii

List of Tables
Page

Table
1

Survey Respondents by the Level of Education they have completed ................. 40

2

Survey Respondents based on their Educational Background .............................. 41

3

Survey Respondents based on their Current Work Setting................................... 42

4

Survey Respondents based on their Current Working Pattern.............................. 43

5

Survey Respondents based on their Experience as a Clinical Research Coordinator

........................................................................................................................................... 44
6

Survey Respondents based on their Experience with the Clinical Monitor.......... 45

7

Survey Respondents based on their Satisfaction with the Skill as well as

Competency of the Monitors ............................................................................................ 46
8

Survey Respondents based on their Satisfaction with the Monitor’s Knowledge

about Protocol and Its Requirements ................................................................................ 47
9

Survey Respondents based on their Satisfaction with the Review for Informed

Violations by the Monitors ............................................................................................... 48
10

Survey Respondents based on the Satisfaction with the Review for Protocol

Deviations by the Monitors ............................................................................................... 49
11

Survey Respondents based on their Satisfaction with the Review for Accuracy of

CRF’s and Source Documents by the Monitors ............................................................... 50

ix

12

Survey Respondents based on their Satisfaction with the Review for Reporting

of Adverse Events by the Monitors .................................................................................. 51
13

Survey Respondents based on their Satisfaction with the Review for Accuracy of

Drug Accountability Records by the Monitors ................................................................. 52
14

Survey Respondents based on their Opinion about the Likeliness of Monitors

Failing to Review the Required Approvals Prior to Study Initiation................................ 53
15

Survey Respondents based on their Judgment about the Likeliness of Monitors

Providing Required Technical Support to the Site Staff................................................... 54
16

Survey Respondents based on their View about the Likeliness of Monitors

Helping the Site Staff in Resolving the Generated Queries .............................................. 55
17

Survey Respondents based on their Opinion about the Likeness of the Monitors

Providing the Monitoring Visit Reports within a Short Time Frame ............................... 56
18

Survey Respondents referring to their Assessment about the Likeliness of

Monitors Increasing the Work Load after the Completion of a Monitoring Visit ............ 57
19

Survey Respondents based on their Judgment, Whether or Not the Quality of

Data at the Site Depends upon the Monitor ...................................................................... 58
20

Survey Respondents based on their Assessment about the Helpfulness of

Monitor in the Preparation of the Site for Audit or Inspection ......................................... 59
21

Survey Responses Expressed by the Clinical Research Coordinators about the

Quality of Monitoring in Clinical Trials today as compared to Five to Ten years ago .... 60

x

List of Figures
Page

Figure
1

Highest Degree or Level of Education Completed by Clinical Research

Coordinators ...................................................................................................................... 40
2

Educational Background of Clinical Research Coordinators ................................. 41

3

Work Setting of the Clinical Research Coordinators .............................................. 42

4

Working Pattern of Clinical Research Coordinators .............................................. 43

5

Experience of Clinical Research Coordinators ....................................................... 44

6

Number of Clinical Trials Interacted With Monitor ............................................... 45

7

Satisfaction of Clinical Research Coordinators with the Skill and Competency of

Monitors ............................................................................................................................ 46
8

Satisfaction of Clinical Research Coordinators with the Monitor’s Understanding

of Protocol and Its Requirements ...................................................................................... 47
9

Satisfaction of Clinical Research Coordinators with the Monitor’s Review of

Informed Consent Process ................................................................................................ 48
10

Satisfaction of Clinical Research Coordinators with the Monitor’s Review for

Protocol Deviations ........................................................................................................... 49
11

Satisfaction of Clinical Research Coordinators with the Monitor’s Review for

Accuracy and Completeness of CRF’s, Source Documents and against Each Other ....... 50

xi

12

Satisfaction of Clinical Research Coordinators with the Monitor’s Review of

Adverse Events ................................................................................................................. 51
13

Satisfaction of Clinical Research Coordinators with the Monitor’s Review of

Drug Accountability Records for Accuracy ..................................................................... 52
14

Likeliness of Monitor Fails To Review IRB and FDA Approvals ....................... 53

15

Likeliness of Technical Support Provided by Monitor’s to Clinical Research

Coordinators ...................................................................................................................... 54
16

Likeliness of Monitors Helping Site Staff ............................................................ 55

17

Likeliness of Monitor Submitting the Monitoring Report within a Short Frame of

Time .................................................................................................................................. 56
18

Likeliness of Monitor Increasing the Work Load after a Monitoring Visit .......... 57

19

How Much the Quality Of Depends Upon Monitor ............................................. 58

20

Helpfulness of Monitor in the Preparation of Audit or Inspection ....................... 59

xii

Chapter 1: Introduction
Clinical Research is a fast-growing, knowledge-based industry with a diverse pool of
clinical research professionals (Gudadhe, 2001). Among the many professionals who play
an important role in clinical research is the clinical monitor or clinical research associate
(CRA). According to ICH GCP (1996), “Monitoring is the act of overseeing the progress
of a clinical trial, and of ensuring that it is conducted, recorded, and reported in
accordance with the protocol, standard operating procedures (SOPs), Good Clinical
Practice (GCP), and the applicable regulatory requirement(s).” The monitor is the “first
line of communication between the sponsor and the investigational site” (Nylen, 2000).
According to ICH GCP (1996), the monitor is responsible for various activities such as:
•

Site selection.

•

Training the site staff.

•

Ensuring that the investigator and site staff are knowledgeable about the protocol
and trial procedures.

•

Protecting the rights, safety, and well-being of human study subjects.

•

Checking the investigational product accountability.

•

Ensuring that the site is following the protocol properly.

•

Reviewing the CRFs, source documents, and informed consent documents.

•

Reviewing of serious adverse event reporting.

•

Helping the site staff in solving the generated queries.

•

Checking whether the investigator has essential documents for the conduct of a
trial (i.e., review of proper documentation at the site).

•

Informing the investigator about the deviations from protocol, SOPs, and GCP
guidelines and taking appropriate action.

Monitors should have scientific as well as clinical knowledge, and they should be
trained adequately concerning the specifics of protocol which they are monitoring (ICH
GCP, 1996). The quality of the clinical trial depends on the monitoring visit reports. Lack
of proper monitoring may lead to many problems. Mihajlovic – Madzarevic (2010)
identified the following problems which can result from inadequately performed
monitoring:
•

Inability to determine whether there has been non – compliance, fraud or
misconduct in the trial.

•

Failure to determine the CRF issues, protocol deviations, and violations.

•

Improper monitoring affecting subject safety and quality of data recorded in the
trial.

The monitor is appointed by a sponsor or a contract research organization to
determine all the inconsistencies (e.g. Protocol deviations, CRF issues etc) in clinical
trials (ICH GCP, 1996). According to Nylen (2000), ensuring proper and accurate
adverse event reporting is one of the major responsibilities of the monitor. However,
common findings from FDA inspections include improper adverse event reporting and
failure to report adverse events to the FDA. Warning letters were issued to clinical
investigators, sponsors, and contract research organizations for inadequate monitoring of
clinical trials (Mihajlovic – Madzarevic, 2010).
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Why are there inconsistencies, if there is a qualified, well-trained, knowledgeable,
and experienced clinical monitor? (Inspection Observations, 2012). Why, then, are
clinical monitors not able to determine the problems and facilitate their solution before
the FDA identifies them?
“The clinical research coordinator (CRC) is a specialized research professional
working with, and under the direction of, the clinical investigator” (Woodin, 2009) and
the responsibilities of clinical research coordinator are:
•

Reviewing and evaluating the protocol.

•

Screening and enrolling the study subjects.

•

Obtaining participant informed consent.

•

Protecting the rights, safety, and well-being of study subjects.

•

Ensuring that study medication was received by eligible subjects.

•

Completing all study documents at the study site properly.

•

Ensuring proper documentation at study site (e.g. Documenting signed informed
consent forms).

•

Submitting all the essentials documents for IRB review.

•

Checking source documents and CRFs thoroughly.

•

Resolving data queries generated by monitor.

•

Proper scheduling of the study subject and monitor visits.

The clinical research coordinator (CRC) plays an important role in study conduct. I
have chosen clinical coordinators for this study, because the CRC is the person at the site
who most frequently interacts with the monitor and will be able to comment most reliably
3

about the monitoring process (Wanna Be a Clinical Research Associate(CRA)? First
Become a CRC!, n.d.).
The current study focuses on the perceptions of clinical coordinators about the quality
of monitoring. The information from this study will inform the identification of the major
inadequacies in the monitoring process and the reasons underlying these inadequacies.
These steps are crucial in developing strategies to improve the monitoring process and
thereby improving the safety as well as the ethical and scientific quality of clinical
research.

4

Chapter 2: Background
According to the Bioresearch Monitoring Program report of 2011, a total of 127 cases
with inconsistencies were reported in Sponsor/Monitor/CRO inspections (Bioresearch
Monitoring (BIMO) Metrics – FY’11, 2011). The most common deficiencies found were:
Failure to report the protocol deviations in monitoring reports from one or more

•

study sites.
Failure to report the informed consent violations in monitoring reports from one

•

or more study sites.
•

Failure to report the IRB reporting violations in monitoring reports.

•

Continuous non-compliance regarding CRFs completion, review, and submission
was determined by the sponsor through other means of communication, but
monitoring reports does not include any of the issues regarding CRFs.
Failure to bring the investigators into compliance:

•

•

According to ICH GCP (1996), the monitor is responsible for ensuring
that the investigator follows approved protocol and amendments (if any).
If the investigator is not adhering to protocol, then it is (initially) the
responsibility of the monitor to bring the investigator into compliance.
However, warning letters were issued to investigators regarding noncompliance in clinical trials.

•

Inadequate accountability for the investigational product (Bertram, 2002):
•

The monitor is responsible for ensuring accurate drug accountability at the
investigational site i.e., monitors should review, documentation regarding
drug accountability, ensure proper drug storage, and log maintenance during
5

monitoring visits. However, findings from the FDA include warning letters
related to drug accountability (Drug Accountability at the Investigative site,
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articl
eDetail.jsp?id=87219).
•

Failure to obtain FDA and IRB approval prior to study initiation:
•

According to ICH GCP (1996), the monitor is responsible for ensuring that
the site has all required approvals before initiation of the study. However,
there are FDA warning letters which cite that the monitor failed in
determining non-compliance.

All of the above are responsibilities of the monitor. In spite of well established
regulations and guidance for monitoring, there are many concerns in clinical trials (e.g.
protocol deviations and violations, IRB violations, improper adverse event reporting, etc).
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Chapter 3: Thesis Statement

Purpose of the Study
The purpose of the study is to determine the perceptions of clinical research
coordinators about quality of monitoring and major inadequacies/concerns in the
monitoring process. Hopefully, data collected will help the sponsors and monitors to
develop solutions for the major concerns relating to the monitoring process.

Research Questions
Question 1:
What are the perceptions of clinical research coordinators about the quality of
monitoring?
Question 2:
What are the major concerns/failings in the monitoring process?
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Chapter 4: Research Design and Methodology

Target Population
Target population refers to the entire group of people or objects or individuals to
which the researcher generalizes the conclusions or study findings (Populations and
Sampling, n.d.). It is also defined as a possible group of respondents to the survey
questions. The target population for this study includes clinical research coordinators.

Sample Population
Sample population (Actual people or respondents selected for survey) is the subset
of a target population and is also called a study population or sample size for the study
(Populations and Sampling, n.d.). The sample population for this study includes 2177
clinical research coordinators from different clinical research sites.

Selection of Sample Size for Survey
Sample size is determined by degree of precision (confidence interval) and
accuracy (confidence level) required for the responses to the survey questions. For this
study, confidence level is 95% and confidence interval is ±10%. Percentages below and
above 50% would have the least amount of variance. Therefore, the sample for this study
is based on a 50% point estimate for any question. Sample size needed to obtain the
desired precision and accuracy is approximately 100 (Macorr research solutions, Sample
size formula, http://www.macorr.com/sample-size-methodology.htm). Anticipating a 4%
to 5% response rate, the survey was sent to 2177 research coordinators (Zoomerang
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online surveys and polls, calculate survey sample size,
http://www.zoomerang.com/sample-size/).

Development of Survey Instrument or Questionnaire
I performed the literature review and summarized the established concerns related
to monitoring. Then I constituted a focus group with three members (Dr. Ronald Maio,
Terry VandenBosch, and Ted Hamilton) at the University of Michigan and conducted
focus group interactions. Then I developed the final questionnaire or survey instrument
by using the suggestions from focus group participants.
The questionnaire or survey questions include six general demographic questions
(e.g. Academic degree, experience level), which provided the demographic information
about coordinators and 15 questions related to monitoring practices (e.g. quality of
monitoring, concerns in monitoring, importance of quality monitoring).
General demographic questions are closed ended (multiple choice questions).
Questions related to monitoring practices include both open ended and closed ended. I
have used the five-point Likert rating scale for closed ended questions related to
monitoring practices and open ended questions are to determine “what is at the tip of the
respondent’s mind” (Brace, 2008).

Human Subjects Protection
Prior to conducting the research or study or survey, I submitted an application for
Review and Approval to conduct research or a survey involving human subjects (Clinical
Research Coordinators) to the College of Health and Human Services Human Subjects
9

Review Committee (CHHS-HSRC) at Eastern Michigan University. The CHHS-HSRC
approved the study to conduct the survey on November 7, 2012. (Appendix A: College
of Health and Human Services Human Subjects Review Committee Approval Letter).
All of the potential participants were informed clearly about the purpose of the
study, procedure for responding to the survey, voluntariness and withdrawal, protecting
the rights of the participant, and contact information by means of Online Survey Consent
Form. (Appendix B: Survey Completion Request or Online Survey Consent Form or
Email Survey).
An Informed consent form or Online Survey Consent Form was mailed
electronically along with the survey. By filling out the survey, the participant agreed to
the conditions of Online Survey Consent Form. If the potential participants decided to
participate, they were told that they could withdraw at anytime, and their participation
was purely voluntary. There are no direct benefits or risks associated with their
participation, and all the responses to the survey are anonymous and confidential.

Method of Data Collection
Finally, with the approval of the Human Subjects Review Committee (HSRC), I
conducted the computer-based survey using Google docs.
I (Investigator) emailed the survey instrument (Appendix C: Survey) including the
email survey consent form to the potential participants following the approval of CHHSHSRC. The survey instrument included the consent form and three mandatory questions
to be answered before they take the short online survey. The purpose of three mandatory
questions is to ensure that the potential participant has read the consent form, voluntarily
10

agrees to take the survey, and participant is a clinical research coordinator (Survey should
be taken only by the clinical research coordinators). Then, it directs the participant to the
survey (Appendix C: Survey). After completing the six demographic questions and 15
questions related to monitoring practices, the participant was directed to click the
“submit” button, which submits their anonymous answers to the investigator.
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Chapter 5: Analysis and Presentation of Data
This chapter is dedicated to presentation of the results of the study which were
obtained by analyzing the data of the responses received.
The basis of this study is quantitative research acquired by collecting the
perceptions of clinical research coordinators about the quality of monitoring through an
electronic survey. The survey was emailed to 2177 potential participants along with a
consent form stating that the survey was completely voluntary and their participation
would remain anonymous. Out of the 2177 potential participants invited to participate in
the study, 92 participants successfully completed the survey and submitted to the
investigator, which represents a 4.23% response rate. Five participants did not meet the
eligibility criteria because they are not clinical research coordinators, and their data or
results were excluded from analysis. Therefore, 87 completed surveys were used in the
final analysis of data.
The electronic survey for this study evaluated the perceptions of clinical research
coordinators about the quality of monitoring and major inadequacies or concerns in the
monitoring process.

Overview of Demographics
The respondents were asked to answer six optional demographic questions before
answering the monitoring practice questions. Demographic questions include their level
of education, educational background, work setting, working pattern, experience as a
clinical research coordinator, and experience in interacting with the monitors. Tables 1 to
6 present the tabulations of the demographic responses.
12

Question 1:
What is the highest degree (or) level of education you have completed?
Survey respondents were asked to select from the following options: (a) High
School Graduate, (b) Associate degree, (c) Bachelor’s degree, (d) Post-baccalaureate
certificate, (e) Master’s degree, (f) Doctorate degree, (g) Other (Please Specify).
The objective of this question was to evaluate whether a majority of the clinical
research coordinators hold a master’s degree.
As shown in Table 1, 42.5% of respondents hold a master’s degree, 41.4% of
respondents hold a bachelor’s degree, 5.7% of respondents hold a doctorate degree, 5.7%
of respondents hold a post baccalaureate certificate, 1.2% of respondents hold an
associate degree, and 3.5% of respondents hold another degree like CFA.
Question 2:
Which of the following best describes your educational background?
Survey respondents were asked to select from the following options: (a) Nursing
degree, (b) Life Science degree (e.g. Pharmacy, Biochemistry, and Biology), (c) Health
Science degree (e.g. Clinical Laboratory Science, Physical Therapy), (d) Clinical
Research degree, (e) Other (Please Specify).
The objective of this question was to evaluate whether a majority of the clinical
research coordinators hold a clinical research degree.
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As shown in Table 2, 28.7% of respondents have a life science degree like
pharmacy, biochemistry, and biology, 21.8% of respondents have a health science degree
like clinical laboratory science, and physical therapy, 23% of respondents have a nursing
degree, 9.2% of respondents have a clinical research degree, and 17.3% of respondents
have degrees in other fields like economics, social work, public health, statistics,
psychology, and clinical social work.
Question 3:
Which of the following best describes your current work setting?
Survey respondents were asked to select from the following options: (a) Private
Practice site, (b) Academic site (University or Teaching Hospitals), (c) Community
Hospital (Not Academically affiliated), (d) Site management organization (organizing a
group of sites centrally to do studies), (e) Contract research organization (company or
organization contracted by a pharmaceutical, medical device or biotechnology company
to conduct clinical trials), (f) Other (please specify).
The objective of this question was to evaluate in what kind of work setting or
organization a majority of the clinical research coordinators are working.
As shown in Table 3, 90.8% of respondents work at academic sites like university
or teaching hospitals, 6.9% of respondents work at private practice sites, and 2.3% of
respondents work at other work settings like non-profit genetic institutes, and community
hospitals affiliated with an academic setting.
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Question 4:
Which of the following describes your current working pattern? (Select all that apply)
Survey respondents were asked to select from the following options: (a) Medical
device clinical trials, (b) Pharmaceutical clinical trials, (c) Investigator—initiated clinical
trials, (d) Government (or) Foundation—sponsored clinical trials, (e) Other (please
specify).
The objective of this question was to evaluate whether a majority of the clinical
research coordinators work on pharmaceutical clinical trials.
As shown in Table 4, 37.1% of respondents work on investigator—initiated
clinical trials, 26.9% of respondents work on government or foundation sponsored
clinical trials, 24.6% of respondents work on pharmaceutical clinical trials, and 11.4% of
respondents work on medical device clinical trials.
Question 5:
About how long have you been working as a clinical research coordinator?
Survey respondents were asked to select from the following options: (a) ≤ 2 years,
(b) > 2 to 5 years, (c) > 5 to 10 years, (d) > 10 years.
The objective of this question was to evaluate the experience of clinical research
coordinators.
As shown in Table 5, 27.9% of respondents have more than 10 years of
experience as a clinical research coordinator, 27.9% of respondents have 5 to 10 years,
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27.9% of respondents have 2 to 5 years, and 16.3% of respondents have 0 to 2 years of
experience as a clinical research coordinator.
Question 6:
How many clinical trials have you participated in where you have interacted with a
monitor?
Survey respondents were asked to select from the following options: (a) 1 to 5, (b)
6 to 10, (c) 11 to 20, (d) > 20.
The objective of this question was to evaluate the experience of clinical research
coordinators with the clinical monitors.
As shown in Table 6, 47.1% of respondents have participated in 1 to 5 trials
where they interacted with the monitor, 23.5% of respondents have participated in more
than 20 trials where they interacted with the monitor, 17.6% of respondents have
participated in 6 to 10 clinical trials where they interacted with the monitor, and 11.8% of
respondents have participated in 11 to 20 clinical trials where they interacted with the
monitor.

Overview of Responses or Reflections based on Monitoring Practice Questions
The respondents were asked to answer 15 questions related to monitoring
practices to evaluate the experiences of clinical research coordinators in relation to
clinical monitoring. Tables 7 to 21 represent the reflections of clinical research
coordinators about the monitoring process or practices.

16

Question 7:
In general, how satisfied are you with the skill and competency of the monitors with
whom you have interacted?
Survey respondents were asked to select from the following options: (a) Very
satisfied, (b) Satisfied, (c) Not sure, (d) Dissatisfied, (e) Very dissatisfied.
The objective of this question was to evaluate what percentage of clinical
monitors are knowledgeable to monitor the clinical trials.
As shown in Table 7, 59.5% of respondents are satisfied with the skill and
competency of monitors, 19.1% of respondents are not sure, 14.3% of respondents are
very satisfied, and 7.1% of respondents are dissatisfied.
Question 8:
In general, how satisfied are you with the monitor’s level of understanding of the
protocol and its requirements?
Survey respondents were asked to select from the following options: (a) Very
satisfied, (b) Satisfied, (c) Not sure, (d) Dissatisfied, (e) Very dissatisfied.
The objective of this question was to evaluate what percentage of monitors are
familiar with the clinical trial protocol and protocol amendments because protocol is the
most important document which is the basis for clinical trial monitoring.
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As shown in Table 8, 60.7% of respondents were satisfied with the monitors
understanding of protocol and its requirements, 21.4% of respondents were very satisfied,
11.9 % of respondents were not sure, and 6.0% of respondents were dissatisfied.
Question 9:
In general, how satisfied are you with the review of the informed consent process
conducted by the monitors with whom you have interacted?
Survey respondents were asked to select from the following options: (a) Very
satisfied, (b) Satisfied, (c) Not sure, (d) Dissatisfied, (e) Very dissatisfied.
The objective of this question was to evaluate to what extent the monitors are
reviewing proper completion and documentation of informed consent process because
informed consent process is the keystone for conducting the research or clinical trial or
clinical study ethically.
As shown in Table 9, 54.8% of respondents were satisfied with the monitors
review of informed consent process, 22.6% of respondents were very satisfied, 19.0% of
respondents were not sure, and 3.6% of respondents were dissatisfied.
Question 10:
In general, how satisfied are you with the review for protocol deviations conducted by the
monitors with whom you have interacted?
Survey respondents were asked to select from the following options: (a) Very
satisfied, (b) Satisfied, (c) Not sure, (d) Dissatisfied, (e) Very dissatisfied.
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The objective of this question was to evaluate whether the monitors are properly
reviewing the protocol deviations in their monitoring visits and discussing about the
issues with the clinical research or trial coordinators for remedial action. Protocol
deviations may affect the patient safety, and quality of data recorded during the trial.
As shown in Table 10, 52.4% of respondents were satisfied with the monitors
review for protocol deviations, 17.9% of respondents were very satisfied, 19.0% of
respondents were not sure, and 10.7% of respondents were dissatisfied.
Question 11:
In general, how satisfied are you with the review for accuracy and completeness of CRF
entries and source documents against each other conducted by the monitors with whom
you have interacted?
Survey respondents were asked to select from the following options: (a) Very
satisfied, (b) Satisfied, (c) Not sure, (d) Dissatisfied, (e) Very dissatisfied.
The objective of this question was to evaluate what percentage of monitors are
detail oriented and comparing the data in the CRF’s with the source documents properly.
This process is very important because it investigates whether reliable, and accurate
information is being reported in the study or not.
As shown in Table 11, 55.9% of respondents were satisfied with the monitors
review for accuracy and completeness of CRF’s against source documents, 22.6% of
respondents were very satisfied, 14.3% of respondents were not sure, 6.0% of
respondents were dissatisfied, and1.2 % of respondents were very dissatisfied.
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Question 12:
In general, how satisfied are you with the review for reporting of adverse events
conducted by the monitors with whom you have interacted?
Survey respondents were asked to select from the following options: (a) Very
satisfied, (b) Satisfied, (c) Not sure, (d) Dissatisfied, (e) Very dissatisfied.
The objective of this question was to evaluate whether monitors are checking the
proper reporting of adverse events and assisting the trial coordinators in correctly
reporting the adverse events. Proper reporting of adverse events is very important in
ensuring the patient safety.
As shown in Table 12, 60.2% of respondents were satisfied with the monitors
review of adverse events, 19.3% of respondents were very satisfied, 12.1% of
respondents were not sure, and 8.4% of respondents were dissatisfied.
Question 13:
In general, how satisfied are you with the review for accuracy of drug accountability
records conducted by the monitors with whom you have interacted?
Survey respondents were asked to select from the following options: (a) Very
satisfied, (b) Satisfied, (c) Not sure, (d) Dissatisfied, (e) Very dissatisfied.
The objective of this question was to evaluate whether monitors are properly
reviewing the drug accountability records to ensure the quality and accuracy of drug
accountability during the course of a trial. Improper drug accountability may affect the
outcome of a clinical trial.
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As shown in Table 13, 53.8% of respondents were satisfied with the monitors
review for accuracy of drug accountability records, 23.7% of respondents were very
satisfied, and 22.5% of respondents were not sure.
Question 14:
In general, how likely are the monitors with whom you have interacted to fail to review
FDA and IRB approvals prior to study initiation?
Survey respondents were asked to select from the following options: (a) Very
Likely, (b) Likely, (c) Not sure, (d) Unlikely, (e) Very Unlikely.
The objective of this question was to evaluate whether monitors are reviewing
required approvals for study initiation because protection of patients is very important in
clinical trials.
As shown in Table 14, 32.2% of respondents indicate that very unlikely monitor’s
fail to review the FDA and IRB approvals prior to study initiation, 29.8% of respondents
indicate unlikely, 22.6% of respondents are not sure, 8.3% of respondents indicate likely,
and 7.1% of respondents indicate very likely.
Question 15:
In general, how likely are the monitors with whom you have interacted to provide
adequate technical support to the site staff about the study?
Survey respondents were asked to select from the following options: (a) Very
Likely, (b) Likely, (c) Not sure, (d) Unlikely, (e) Very Unlikely.
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The objective of this question was to evaluate whether monitors are supporting
and helping the site staff during the course of a clinical trial.
As shown in Table 15, 47.6 % of respondents indicate that the monitors likely
provide the technical support, 20.7% of respondents indicate very likely, 17.1% of
respondents were not sure, 12.2% of respondents indicate unlikely, and 2.4% of
respondents indicate very unlikely.
Question 16:
In general, how likely are the monitors with whom you have interacted to help the site
staff in resolving the generated queries?
Survey respondents were asked to select from the following options: (a) Very
Likely, (b) Likely, (c) Not sure, (d) Unlikely, (e) Very Unlikely.
The objective of this question was to evaluate whether monitors are helping the
site staff in addressing the queries properly and resolving them.
As shown in Table 16, 50.0% of respondents believe that monitors likely help the
site staff in resolving the queries, 32.1% of respondents believe that very likely monitors
help the site staff in resolving queries, 10.7% of respondents believe that unlikely
monitors help the site staff in resolving the queries, and 7.2% of respondents were not
sure.
Question 17:
In general, how likely are the monitors with whom you have interacted to provide site
monitoring reports in a short time frame after completing a monitoring visit?
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Survey respondents were asked to select from the following options: (a) Very
Likely, (b) Likely, (c) Not sure, (d) Unlikely, (e) Very Unlikely.
The objective of this question was to evaluate whether the monitors are providing
the monitoring reports within the time frame stating any issues that were observed during
monitoring inspection. Monitoring reports are very helpful in addressing the issues during
the study and ensure the progress of a clinical trial.
As shown in Table 17, 54.9% of respondents believe that monitors likely provide
the monitoring report within short time frame, 18.3% of respondents believe very likely
to provide the monitoring report within short time frame, 14.6% of respondents were not
sure, 11.0% of respondents indicate that monitors unlikely provide the monitoring report
within the short time frame, and 1.2% of respondents indicate that very unlikely monitors
provide the monitoring report within the short time frame.
Question 18:
In general, how likely is it that there is an increase in work load following the completion
of a monitoring visit?
Survey respondents were asked to select from the following options: (a) Very
Likely, (b) Likely, (c) Not sure, (d) Unlikely, (e) Very Unlikely.
The objective of this question was to evaluate whether the monitors are increasing
the workload of the site staff due monitoring visit or helping the site staff in addressing
the issues properly in turn decreasing the workload of clinical research coordinators.
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As shown in Table 18, 42.2% of respondents reveal that monitors likely increase
the work load after the monitoring visit, 36.1% indicate very likely, 12.0% represent
unlikely, and 9.7% of respondents are not sure.
Question 19:
In general, in a clinical study, how much do you believe the quality of the data at your
site reflects upon the monitors with whom you have interacted?
Survey respondents were asked to select from the following options: (a) Very
much, (b) Moderately, (c) Not sure, (d) Minimally, (e) Does not reflect.
The objective of this question was to evaluate whether the quality of data and
success of a clinical trial will depend on the monitor or not.
As shown in Table 19, 39.8% of respondents believe quality of data depends
moderately upon monitor, 27.7% of respondents believe that quality of data depends very
much upon monitor, 16.9% of respondents are not sure, and15.6 % of respondents
believe that quality of data minimally depends upon monitor.
Question 20:
Has your site been audited or inspected in the past 3 years? If so, has the monitor been
helpful in preparation for the audit or inspection?
Survey respondents were asked to select from the following options: (a) Very
much, (b) Moderately, (c) Not sure, (d) Minimally, (e) Not at all.

24

The objective of this question was to evaluate whether the monitor is helping the
site staff in reporting the accurate data according to the protocol, SOP’s, GCP’s and
applicable regulatory requirements. A clinical trial audit is necessary to protect the
subjects and to ensure that the trail is conducted according to the required regulations.
As shown in Table 20, 37.5% of respondents are not sure about the monitors help
in the preparation of audit or inspection, 27.8% of respondents believe that monitor was
helpful moderately in the preparation for the audit, 13.9% of respondents indicate that
monitor was not at all helpful in the preparation for the audit or inspection, 12.5% of
respondents reveal that monitor was very much helpful, and 8.3% of respondents believe
that monitor was minimally helpful.
Question 21:
In general, what is your opinion about the quality of monitoring in clinical trials today as
compared to 5-10 years ago?
The objective of this question was to evaluate whether the quality monitoring was
increasing day by day or decreasing.
This is an open ended question, and respondents were allowed to write their own
comments about the quality of monitoring. The responses to this question were tabulated
in Table 21.

Summary of Results/Findings based on the Data Collected
•

42.5% of the clinical research coordinators who responded hold a master’s
degree.
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•

9.2% of clinical research coordinators who responded have a clinical research
degree and that the majority of the clinical research coordinators have a degree in
a life science, e.g. pharmacy, bio-chemistry and biology.

•

90.8% of the clinical research coordinators who responded work at sites which are
affiliated with a university or teaching hospital.

•

37.1% of the clinical research coordinators who responded are working on
investigator-initiated clinical trials.

•

83.7% of respondents have more than two years of experience as a clinical
research coordinator.

•

47.1% of the clinical research coordinators who responded have participated in at
least one clinical trial where they have interacted with a monitor.

•

Only 14.3% of the clinical research coordinators who responded were very
satisfied with the monitors who visited them, but most (59.5%) of the clinical
research coordinators were satisfied with the skill and competency of the monitors
with whom they have interacted.

•

Only 21.4% of clinical research coordinators who responded were very satisfied,
and most (60.7%) of the clinical research coordinators were satisfied with the
monitor’s level of understanding of the protocol and its requirements.

•

22.6% of the clinical research coordinators who responded were very satisfied,
and 54.8% of the clinical research coordinators were satisfied with the review of
the informed consent process conducted by the monitors with whom they have
interacted.
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•

17.9% of the clinical research coordinators who responded were very satisfied,
and more than half (52.4%) of the clinical research coordinators were satisfied
with the review for protocol deviations conducted by the monitors with whom
they have interacted.

•

22.6% of the clinical research coordinators who responded were very satisfied,
whereas 55.9% of clinical research coordinators were satisfied with the monitors
review for the accuracy and completeness of CRF’s and source documents.

•

Only 19.3% of the clinical research coordinators who responded were very
satisfied, and 60.2% of the clinical research coordinators were satisfied with the
monitors review for reporting of adverse events.

•

23.7% of the clinical research coordinators who responded were very satisfied,
and 53.8% were satisfied with the monitors review for accuracy of drug
accountability records.

•

29.8% of the clinical research coordinators who responded indicated unlikely,
whereas 32.2% of clinical research coordinators indicate that it is very unlikely
that monitors fail to review the FDA and IRB approvals prior to study initiation.

•

20.7 % of the clinical research coordinators who responded indicated that the
monitor is very likely to provide the technical support (e.g. helping site staff in
resolving the enrollment barrier, training the site staff, and helping the site staff in
resolving the issues encountered during the conduct of the study), and 47.6% of
respondents indicate that the monitors likely provide the technical support.

•

50.0% of the clinical research coordinators who responded indicated that the
monitors are likely to help the site staff in resolving the generated queries,
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whereas 32.1% of clinical research coordinators indicated that it is very likely that
monitors help the site staff in resolving queries.
•

54.9% of the clinical research coordinators who responded indicated that the
monitors are likely to provide the monitoring report within a short time after the
visit, and 18.3% of clinical research coordinators indicated that the monitors are
very likely to provide the monitoring report within a short time after the visit.

•

88.0% of the clinical research coordinators who responded indicated that the
monitors are likely to increase the work load after the completion of a monitoring
visit.

•

27.7% of the clinical research coordinators who responded believe that the quality
of trial data depends very much upon the monitor, and 39.8% of the clinical
research coordinators believe that the quality of trial data depends moderately
upon the monitor.

•

12.5% of respondents indicated that the monitor was very much helpful, and
27.8% of respondents believe that monitor was moderately helpful in the
preparation for an audit or inspection of the site.
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Chapter 6: Summary, Conclusion, and Inferences
The objective of this study was to determine the perceptions of the clinical
research coordinators about the quality of clinical monitoring. The author of this report
thinks that there are some problems in the monitoring of clinical trials based on the
warning letters issued to clinical investigators, sponsors, and CROs for inadequate
monitoring of clinical trials. Therefore, he is interested in finding the reasons for
improper monitoring and major concerns in the monitoring process as well as perceptions
of clinical research coordinators about the quality of monitoring.
The data from this study suggest that there are issues or problems in the
monitoring of clinical trials based on the perceptions of clinical research coordinators.
This study found that majority of the clinical research coordinators participating
in the study have either a master’s degree or bachelor’s degree in life science (pharmacy,
biology, and bio-chemistry) or nursing, majority are working at academic sites like
university or teaching hospitals, and the majority participated in all kinds of clinical trials
like medical device clinical trials, pharmaceutical clinical trials, investigator-initiated
clinical trials, and government or foundation sponsored clinical trials. Also, a majority of
the clinical research coordinators participating in this study have more than 2 years of
experience in clinical trials and have interacted with the monitor in at least one clinical
trial. Results also indicate that very few of the clinical research coordinators have a
clinical research degree.
Based on the responses to the monitoring practice questions, majority of the
clinical research coordinators are satisfied with the skill and competency of monitors, the
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monitor’s level of understanding of the protocol and its requirements, the monitor’s
review for the informed consent process violations, the monitor’s review for the protocol
deviations, the monitor’s review for accuracy and completeness of CRF’s (case report
form) as well as source documents, the monitor’s review for proper reporting of adverse
events, and the monitor’s review for accuracy of drug accountability records. They also
indicate that the monitors review the IRB and FDA approvals before the study initiation,
provide adequate technical support to the site staff about the study and also the
monitoring reports within a short time frame, and help the site staff in resolving the
generated queries and also in the preparation of the site for audits or inspections. Results
also reveal that most of the clinical research coordinators believe that the quality of data
in a clinical trial depends upon the monitor.
On the other hand, a majority of the clinical research coordinators participated in
this study stated that the monitors are increasing the workload after the completion of a
monitoring visit. Although a majority of the coordinators are satisfied with the work done
by the monitors, some of the clinical research coordinators are not satisfied with the skill
of monitors, the monitor’s protocol knowledge, and the monitor’s review for the
problems in the informed consent process as well as with the monitor’s review for
protocol deviations. Also, they are not satisfied with the monitor’s review for accuracy
and completeness of CRF’s as well as the source documents review, review for proper
reporting of adverse events. They also state that the monitors fail to review the required
approvals before the study initiation, do not provide the adequate technical support for
the study, do not help the site staff in resolving the generated queries as well as in the
preparation of the site for audits or inspections, and will not provide the monitoring visit
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report quickly or within the time frame. Very few clinical research coordinators believe
that the quality of data minimally depends upon the monitor.

Major Concerns or Problems in the Monitoring Process
Following are the major concerns or problems in the monitoring process based on the
percent of response by the clinical research coordinators:
•

Monitors are increasing the work load on clinical research coordinators after the
monitoring visit.

•

Monitors failed to review the required approvals like FDA and IRB approvals
prior to the study initiation.

•

Monitors failed to provide the technical support to the site staff during the course
of a clinical trial.

•

Monitors are not providing the support to the site staff in the preparation of the
site for the inspection or audit.

•

Monitors are not providing the monitoring visit reports within a short time frame.

•

Monitors failed to review the protocol deviations properly.

•

Monitors are not supporting or helping the site staff properly in the process of
solving the generated queries.

•

Monitors failed to review the proper reporting of adverse events.

•

Monitors failed to review the accuracy as well as the completeness of CRF’s and
source documents.

•

Some monitors do not have the required skills and knowledge.

•

Monitors do not have the required protocol knowledge.
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•

Monitors failed to review the informed consent process properly.

Clinical Research Coordinators Perceptions about the Quality of Monitoring
Perceptions of clinical research coordinators about the quality of monitoring are
quite variable. Based on the responses given to the open-ended question about quality of
monitoring, some clinical research coordinators believe that the quality of monitoring has
increased compared to the monitoring five to ten years ago. Some clinical research
coordinators believe that there is minimal improvement in monitoring and some other
coordinators believe that there is no significant change in the quality of monitoring. But
the majority of the clinical research coordinators conclude that the overall quality of the
clinical monitoring has decreased.
Perhaps the study coordinator’s perceived quality of monitoring varies from
monitor to monitor because some clinical research associates are trained well and they
have good knowledge about the study as well as about the applicable regulations. Also,
perhaps perceptions could be affected by the fact that some clinical research coordinators
have positive experience with the monitors, whereas some clinical research coordinators
have a hard time in working with the monitors.

Reasons for Decreased Quality of Monitoring
Based on the findings of this study, the author suggests the following:
•

Monitors are not trained or mentored well.

•

Monitors have inadequate knowledge.

•

Monitors have a lack of adequate experience as a clinical research associate.
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•

Monitors were changed during the course of the study.

•

Monitors are overwhelmed with too many sites or too many studies.

How Can we Improve the Quality of Monitoring?
The quality of monitoring can be improved by training the clinical research
associates adequately according to the industry standards, which in turn depends on the
CROs, sponsors, or monitoring company for which the monitors are working. Skills of
the clinical trial monitors can also be improved by encouraging them to attend the
conferences related to clinical monitoring.
Clinical monitors should be trained in such a way that the monitors have a good
understanding of the protocol as well as the SOPs related to the study on which they will
be working (SPONSOR, n.d). Clinical monitors need to have the appropriate and
adequate clinical knowledge as well as scientific knowledge required to monitor the
clinical trials adequately (ICH GCP, 1996). Proper planning by the monitors can also
help in reflecting quality data (The art and science of monitoring, 2001).
Decrease the workload of the clinical monitors, which can be done by decreasing
the number of protocols or studies or sites they are responsible for monitoring and also by
increasing the number of clinical monitors for the purpose of monitoring the studies
(Kenneth, 2012). Have the same monitor for the study until the study closes. If the
monitors change frequently during the study, it disturbs the way the study is done and the
quality of monitoring decreases. It also decreases the proper communication between the
site staff and monitors. Improve the communication power or capability of clinical
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monitors with other the monitors, sponsors, investigators as well as with the site staff
during the conduct of the clinical trial (The art and science of monitoring, 2001).
Implementation of the correct monitoring procedures increases quality of monitoring.
The quality of monitoring can also be increased by hiring the monitors with required
qualifications as well as with the adequate experience in the monitoring or as a clinical
research coordinator. Prior experience as a clinical research coordinator enables the
monitors to efficiently find and help in correcting the problems (Wanna Be a Clinical
Research Associate [CRA]? First Become a CRC!, n.d.).
Finally, through excellent coordination and team work we can improve the quality
of monitoring as well as quality of data reflected in the clinical trials, which paves a path
for the success of a clinical trial.

Conclusion
This research study suggests that there are still concerns about the monitoring
process, which affect the quality of monitoring, which in turn which may have impact on
the quality of data reflected in the study as well as on the success of a clinical trial.
Effective monitoring can be achieved by addressing the issues in the process of
monitoring through which we can protect the subjects as well as improve the health of
subjects.
Effective clinical monitoring ensures that the clinical trial is conducted, recorded,
and reported in accordance with the protocol’s standard operating procedures (SOPs),
good clinical practice (GCP), and the applicable regulatory requirement(s), which dictates
that the clinical trials should be conducted according to the ethical principles necessary
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for the proper conduct of a clinical trial. This can be achieved through qualified,
competent, and knowledgeable monitors.
Monitors should be trained effectively, as they are ultimately responsible for the
success of a clinical trial. Monitors should be knowledgeable about the trial documents,
clinical or study protocol, Good Clinical Practice (GCP), Standard Operating Procedures
(SOPs), local and state laws and other applicable regulations, research ethics and study
conduct issues, and the ethical issues that they may encounter during conduct of a clinical
trial.
Monitors should be proficient in finding the concerns related to the approved
protocol, informed consent documents as well as the process, SOPs, reporting of adverse
events, participant’s inclusion criteria for the study, clinical trial documentation, and site
facilities. Also monitors have to check whether the investigators and the study team are
qualified and knowledgeable. The monitor is also responsible for ensuring whether
participant confidentiality is maintained.
Responsible clinical monitoring ensures the protection of participants and their
rights while meeting the GCP standards and regulations and properly following the
protocol and SOPs. An effective clinical monitor is responsible for finding the problems
in the study as well as with the data recorded in the trial and ensuring the compliance as
well as the progress of a clinical trial. Success of the research project or clinical trial or
study depends on choosing the right trained, knowledgeable, and experienced monitoring
team.
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In summary, the monitor is responsible for the successful execution of a clinical
study. By strengthening the communication between the site staff and the monitor, clean
and quality data can be acquired by following the applicable regulations as well as
protecting the rights and safety of participants or subjects. Monitors’ roles are very
valuable because they help in guiding the new medications to the market and directly
affect the health of the participants around the country as well as at the global level.

Limitations and Recommendations for Future Research
There are some limitations for this study. First, the overall response rate was only
4.23%. Second, the sample of this study is limited to clinical research coordinators, and
most of the respondents were working at sites which are affiliated with a university or a
teaching hospital. Also, the respondents are primarily working on the investigatorinitiated clinical trials. Therefore, my responding sample may not be representative, and
the results of this study are limited to the perceptions and experiences of the sample
group.
Through this study, the author has provided evidence to suggest that there are still
concerns in clinical monitoring despite the presence of the well established regulations
for monitoring practice. A similar study can be done or replicated with a larger sample,
which would enhance the validity and reliability of the conclusions reached. This study
captured and examined only the perceptions of clinical research coordinators, which is a
select population. A more broad population of clinical research professionals would
likely provide wide range of monitoring practice concerns as well as wide range of
perceptions about the quality of monitoring.
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Demographic Profile of Clinical Research Coordinators
Table 1
Survey Respondents by the Level of Education they have completed
Response or Answer

Frequency Percent (%)

Cumulative Cumulative
Frequency Percent (%)

High School Graduate

0

0%

0

0%

Associate degree

1

1.2%

1

1.2%

Bachelor’s degree

36

41.4%

37

42.6%

Post-baccalaureate certificate 5

5.7%

42

48.3%

Master’s degree

37

42.5%

79

90.8%

Doctorate degree

5

5.7%

84

96.5%

Other

3

3.5%

87

100.0%

TOTAL

87

100%

Education Level
50%
40%
30%
20%
10%
0%

42.50%

41.40%

0%

1.20%

5.70%

5.70% 3.50%

Figure 1. Highest Degree or Level of Education Completed by Clinical Research
Coordinators
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Table 2
Survey Respondents based on their Educational Background
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

Nursing degree

20

23%

20

23%

Life Science degree
(e.g. Pharmacy,
Biochemistry,
Biology)

25

28.7%

45

51.7%

Health Science degree
(e.g. Clinical
Laboratory Science,
Physical Therapy)

19

21.8%

64

73.5%

Clinical Research degree 8

9.2%

72

82.7%

Other

17.3%

87

100.0%

15

TOTAL

87

100%

Education Background
35%
28.70%

30%
25%

23%

21.80%

20%

17.30%

15%

9.20%

10%
5%
0%
Nursing Life science
degree
degree

Health
science
degree

Clinical
research
degree

Other

Figure 2. Educational Background of Clinical Research Coordinators
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Table 3
Survey Respondents based on their Current Work Setting
Response or Answer

Frequency

Percent (%)

Cumulative Cumulative
Frequency Percent (%)

Private Practice site

6

6.9%

6

6.9%

Academic site
(University or
Teaching Hospitals)

79

90.8%

85

97.7%

Community Hospital
(Not Academically
affiliated)

0

0%

85

97.7%

Site management
organization

0

0%

85

97.7%

Contract research
organization

0

0%

85

97.7%

Other

2

2.3%

87

100.0%

TOTAL

87

100%

Work Setting
100.00%
80.00%
60.00%
40.00%
20.00%
0.00%

90.80%

6.90%

0%

0%

0%

2.30%

Figure 3. Work Setting of the Clinical Research Coordinators
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Table 4
Survey Respondents based on their Current Working Pattern
Response or Answer

Frequency

Percent (%)

Cumulative Cumulative
Frequency Percent (%)

Medical device
clinical trials

19

11.4%

19

11.4%

Pharmaceutical
clinical trials

41

24.6%

60

36.0%

Investigator - initiated
clinical trials

62

37.1%

122

73.1%

Government (or)
Foundation – sponsored
clinical trials

45

26.9%

167

100.0%

Other

0

0%

167

100.0%

TOTAL

167
100%
People may select more than one check box or response, that’s why

respondents number (N=167) is more than 87 (number of people actually responded).

Working Pattern
40.00%
35.00%
30.00%
25.00%
20.00%
15.00%
10.00%
5.00%
0.00%

37.10%
26.90%

24.60%
11.40%

0%

Figure 4. Working Pattern of Clinical Research Coordinators
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Table 5
Survey Respondents based on their Experience as a Clinical Research Coordinator
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

≤ 2 years

14

16.3%

14

16.3%

> 2 to 5 years

24

27.9%

38

44.2%

> 5 to 10 years

24

27.9%

62

72.1%

> 10 years

24

27.9%

86

100.0%

TOTAL

86

100%

CRC's Experience
30.00%

27.90%

27.90%

27.90%

25.00%
20.00%

16.30%

15.00%
10.00%
5.00%
0.00%
< 2 years

> 2 to 5 years > 5 to 10 years

> 10 years

Figure 5. Experience of Clinical Research Coordinators
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Table 6
Survey Respondents based on their Experience with the Clinical Monitor
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

1 to 5

40

47.1%

40

47.1%

6 to 10

15

17.6%

55

64.7%

11 to 20

10

11.8%

65

76.5%

> 20

20

23.5%

85

100.0%

TOTAL

85

100%

Clinical Trials - Monitor
50.00%

47.10%

45.00%
40.00%
35.00%
30.00%
23.50%

25.00%
20.00%

17.60%

15.00%

11.80%

10.00%
5.00%
0.00%
1 to 5

6 to 10

11 to 20

> 20

Figure 6. Number of Clinical Trials Interacted With Monitor
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Presentation of Responses to Monitoring Practice Questions
Table 7
Survey Respondents based on their Satisfaction with the Skill as well as Competency of
the Monitors
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

Very satisfied

12

14.3%

12

14.3%

Satisfied

50

59.5%

62

73.8%

Not sure

16

19.1%

78

92.9%

Dissatisfied

6

7.1%

84

100.0%

Very dissatisfied

0

0%

84

100.0%

TOTAL

84

100%

Monitor Skill and Competency
70.00%
59.50%

60.00%
50.00%
40.00%
30.00%
20.00%

19.10%

14.30%

7.10%

10.00%

0.00%

0.00%
Very
satisfied

Satisfied

Not sure

Dissatisfied

Very
dissatisfied

Figure 7. Satisfaction of Clinical Research Coordinators with the Skill and Competency
of Monitors
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Table 8
Survey Respondents based on their Satisfaction with the Monitor’s Knowledge about
Protocol and Its Requirements
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

Very satisfied

18

21.4%

18

21.4%

Satisfied

51

60.7%

69

82.1%

Not sure

10

11.9%

79

94.0%

Dissatisfied

5

6.0%

84

100.0%

Very dissatisfied

0

0%

84

100.0%

TOTAL

84

100%

Protocol Understanding
70.00%
60.70%

60.00%
50.00%
40.00%
30.00%

21.40%

20.00%

11.90%
6.00%

10.00%

0.00%
0.00%
Very
satisfied

Satisfied

Not sure

Dissatisfied

Very
dissatisfied

Figure 8. Satisfaction of Clinical Research Coordinators with the Monitor’s
Understanding of Protocol and Its Requirements
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Table 9
Survey Respondents based on their Satisfaction with the Review for Informed Violations
by the Monitors
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

Very satisfied

19

22.6%

19

22.6%

Satisfied

46

54.8%

65

77.4%

Not sure

16

19.0%

81

96.4%

Dissatisfied

3

3.6%

84

100.0%

Very dissatisfied

0

0%

84

100.0%

TOTAL

Informed Consent Process
60.00%

54.80%

50.00%
40.00%
30.00%

22.60%

20.00%

19.00%

10.00%
3.60%

0.00%

0.00%

Figure 9. Satisfaction of Clinical Research Coordinators with the Monitor’s Review of
Informed Consent Process
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Table 10
Survey Respondents based on the Satisfaction with the Review for Protocol Deviations by
the Monitors
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

Very satisfied

15

17.9%

15

17.9%

Satisfied

44

52.4%

59

70.3%

Not sure

16

19.0%

75

89.3%

Dissatisfied

9

10.7%

84

100.0%

Very dissatisfied

0

0.0%

84

100.0%

TOTAL

84

100%

Protocol Deviations
60.00%

52.40%

50.00%
40.00%
30.00%
20.00%

19.00%

17.90%

10.70%
10.00%
0.00%
0.00%
Very
satisfied

Satisfied

Not sure

Dissatisfied

Very
dissatisfied

Figure 10. Satisfaction of Clinical Research Coordinators with the Monitor’s Review for
Protocol Deviations

49

Table 11
Survey Respondents based on their Satisfaction with the Review for Accuracy of CRF’s
and Source Documents by the Monitors
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

Very satisfied

19

22.6%

19

22.6%

Satisfied

47

55.9%

66

78.5%

Not sure

12

14.3%

78

92.8%

Dissatisfied

5

6.0%

83

98.8%

Very dissatisfied

1

1.2%

84

100.0%

TOTAL

84

100%

CRF's Review
60.00%

55.90%

50.00%
40.00%
30.00%

22.60%

20.00%

14.30%

10.00%

6.00%
1.20%

0.00%
Very
satisfied

Satisfied

Not sure

Dissatisfied

Very
dissatisfied

Figure 11. Satisfaction of Clinical Research Coordinators with the Monitor’s Review for
Accuracy and Completeness of CRF’s, Source Documents and against Each Other
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Table 12
Survey Respondents based on their Satisfaction with the Review for Reporting of Adverse
Events by the Monitors
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

Very satisfied

16

19.3%

16

19.3%

Satisfied

50

60.2%

66

79.5%

Not sure

10

12.1%

76

91.6%

Dissatisfied

7

8.4%

83

100.0%

Very dissatisfied

0

0.0%

83

100.0%

TOTAL

83

100%

Adverse Events Review
70.00%
60.20%

60.00%
50.00%
40.00%
30.00%
20.00%

19.30%
12.10%

10.00%

8.40%
0.00%

0.00%
Very
satisfied

Satisfied

Not sure

Dissatisfied

Very
dissatisfied

Figure 12. Satisfaction of Clinical Research Coordinators with the Monitor’s Review of
Adverse Events
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Table 13
Survey Respondents based on their Satisfaction with the Review for Accuracy of Drug
Accountability Records by the Monitors
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

Very satisfied

19

23.7%

19

23.7%

Satisfied

43

53.8%

62

77.5%

Not sure

18

22.5%

80

100.0%

Dissatisfied

0

0.0%

80

100.0%

Very dissatisfied

0

0.0%

80

100.0%

TOTAL

80

100%

Drug Accountability Records Review
60.00%

53.80%

50.00%
40.00%
30.00%

23.70%

22.50%

20.00%
10.00%
0.00%

0.00%

Dissatisfied

Very
dissatisfied

0.00%
Very
satisfied

Satisfied

Not sure

Figure 13. Satisfaction of Clinical Research Coordinators with the Monitor’s Review of
Drug Accountability Records for Accuracy
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Table 14
Survey Respondents based on their Opinion about the Likeliness of Monitors Failing to
Review the Required Approvals Prior to Study Initiation
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

Very Likely

6

7.1%

6

7.1%

Likely

7

8.3%

13

15.4%

Not sure

19

22.6%

32

38.0%

Unlikely

25

29.8%

57

67.8%

Very Unlikely

27

32.2%

84

100.0%

TOTAL

84

100%

FDA and IRB Approval Review
35.00%
29.80%

30.00%
25.00%

32.20%

22.60%

20.00%
15.00%
10.00%

7.10%

8.30%

Very likely

Likely

5.00%
0.00%
Not sure

Unlikely

Very
unlikely

Figure 14. Likeliness of Monitor Fails To Review IRB and FDA Approvals
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Table 15
Survey Respondents based on their Judgment about the Likeliness of Monitors Providing
Required Technical Support to the Site Staff
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

Very Likely

17

20.7%

17

20.7%

Likely

39

47.6%

56

68.3%

Not sure

14

17.1%

70

85.4%

Unlikely

10

12.2%

80

97.6%

Very Unlikely

2

2.4%

82

100.0%

TOTAL

82

100%

Monitor Technical Support
50.00%
45.00%
40.00%
35.00%
30.00%
25.00%
20.00%
15.00%
10.00%
5.00%
0.00%

47.60%

20.70%
17.10%
12.20%
2.40%
Very likely

Likely

Not sure

Unlikely

Very
unlikely

Figure 15. Likeliness of Technical Support Provided by Monitor’s to Clinical Research
Coordinators
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Table 16
Survey Respondents based on their View about the Likeliness of Monitors Helping the
Site Staff in Resolving the Generated Queries
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

Very Likely

27

32.1%

27

32.1%

Likely

42

50.0%

69

82.1%

Not sure

6

7.2%

75

89.3%

Unlikely

9

10.7%

84

100.0%

Very Unlikely

0

0.0%

84

100.0%

TOTAL

84

100%

Monitor's Helping Site Staff
60.00%
50.00%

50.00%
40.00%
32.10%
30.00%
20.00%

7.20%

10.00%

10.70%
0.00%

0.00%
Very likely

Likely

Not sure

Unlikely

Figure 16. Likeliness of Monitors Helping Site Staff
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Very
unlikely

Table 17
Survey Respondents based on their Opinion about the Likeness of the Monitors Providing
the Monitoring Visit Reports within a Short Time Frame
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

Very Likely

15

18.3%

15

18.3%

Likely

45

54.9%

60

73.2%

Not sure

12

14.6%

72

87.8%

Unlikely

9

11.0%

81

98.8%

Very Unlikely

1

1.2%

82

100.0%

TOTAL

82

100%

Monitoring Report Submission Time
60.00%

54.90%

50.00%
40.00%
30.00%
20.00%

18.30%
14.60%
11.00%

10.00%
1.20%
0.00%
Very likely

Likely

Not sure

Unlikely

Very unlikely

Figure 17. Likeliness of Monitor Submitting the Monitoring Report within a Short Frame
of Time
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Table 18
Survey Respondents referring to their Assessment about the Likeliness of Monitors
Increasing the Work Load after the Completion of a Monitoring Visit
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

Very Likely

30

36.1%

30

36.1%

Likely

35

42.2%

65

78.3%

Not sure

8

9.7%

73

88.0%

Unlikely

10

12.0%

83

100.0%

Very Unlikely

0

0.0%

83

100.0%

TOTAL

83

100%

Work Load Increase
45.00%
40.00%

42.20%
36.10%

35.00%
30.00%
25.00%
20.00%
15.00%

12.00%
9.70%

10.00%
5.00%

0.00%
0.00%
Very likely

Likely

Not sure

Unlikely

Very unlikely

Figure 18. Likeliness of Monitor Increasing the Work Load after a Monitoring Visit
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Table 19
Survey Respondents based on their Judgment, Whether or Not the Quality of Data at the
Site Depends upon the Monitor
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

Very much

23

27.7%

23

27.7%

Moderately

33

39.8%

56

67.5%

Not sure

14

16.9%

70

84.4%

Minimally

13

15.6%

83

100.0%

Does not reflect

0

0.0%

83

100.0%

TOTAL

83

100%

Data Quality
45.00%
39.80%

40.00%
35.00%
30.00%

27.70%

25.00%
20.00%

16.90%

15.60%

15.00%
10.00%
5.00%
0.00%
0.00%
Very much

Moderately

Not sure

Minimally

Does not
reflect

Figure 19. How Much the Quality Of Depends Upon Monitor
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Table 20
Survey Respondents based on their Assessment about the Helpfulness of Monitor in the
Preparation of the Site for Audit or Inspection
Response or Answer

Frequency

Percent (%)

Cumulative
Frequency

Cumulative
Percent (%)

Very much

9

12.5%

9

12.5%

Moderately

20

27.8%

29

40.3%

Not sure

27

37.5%

56

77.8%

Minimally

6

8.3%

62

86.1%

Not at all

10

13.9%

72

100.0%

TOTAL

72

100%

Audit or Inspection Preparation
40.00%

37.50%

35.00%
30.00%

27.80%

25.00%
20.00%
15.00%

13.90%

12.50%

10.00%

8.30%

5.00%
0.00%
Very much

Moderately

Not sure

Minimally

Not at all

Figure 20. Helpfulness of Monitor in the Preparation of Audit or Inspection
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Table 21
Survey Responses Expressed by the Clinical Research Coordinators about the Quality of
Monitoring in Clinical Trials Today as Compared to Five to Ten Years Ago
Quality of monitoring has increased.
Monitors are better prepared now.
Quality of monitoring is very good.
There is minimal improvement.
All the monitors, I have dealt with are exceptional.
More thorough, very particular about following GCP and keeping clean data.
To me, the quality of monitoring in clinical trials has dramatically increased due to the
electronic technology improvement as compared to 5-10 years ago.
I mostly worked on NIH sponsored trials in basic science and there is no monitoring. I
did work on one clinical trial for a drug company sponsor and the monitors are proficient.
Study monitors can be inconsistent, especially when monitors change during the study.
Compared to earlier, the consistency as well as overall quality has improved.
The monitors I have worked with are very helpful in variety of ways. In particular, one
monitor was very useful in determining what exactly the CRF’s were asking and
educated me about some parameters and measures. Other monitor focuses on regulatory
aspects and data review for accuracy, it is a great help in going to the sponsor to clarify
any questions we have.
It’s getting slightly better; the best monitor’s are the ones who have worked as a
coordinator before. Most likely, they know where to look and what common things
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should be corrected?
Each monitor is different and most of them are well trained, knowledgeable and eager to
help.
No significant change in monitoring.
Quality of monitoring is same and study monitoring depends on the complexity of the
study that we are doing at the time of the monitoring visit.
I think there are many new monitors who are not being trained or mentored as well as
may have been the case 5-10 years ago.
The quality of monitoring is not as good as 5-10 years ago. From my experiences, the
monitors today are overwhelmed with too many sites or too many studies.
I feel the quality of monitoring five years ago was much better than today. Today
monitors are overwhelmed with workloads and they don’t really have the knowledge,
some of them don’t have experience.
I have seen a dramatic decrease in the experience and competence of monitors visiting
my site during the past five years. In general, there are good monitors (certain CRO’s).
Every monitor does things differently; they all want us to do things differently and don’t
understand our IRB procedures as well as operating procedures.
Varies by monitor. Monitors does not look at the data in the same way FDA does i.e.,
monitors focus on verifying data and do not look for inconsistencies.
I feel the quality of monitoring has gone down because monitors are over worked.
Monitoring quality has gone down because of the amount of sites and patients the
monitors are responsible for.
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Many companies are using in – house monitors, instead of a monitoring company and
many in-house monitors are not versed with the correct monitoring procedures.
Monitors change frequently during the course of the study and data requirements change
from monitor to monitor. Some monitors have been the way too demanding of time or
schedule and they don’t even understand that the coordinators have multiple studies or
commitments. Either the sponsor needs to invest in training or increase number of
monitors to avoid the huge turnover in industry studies.
I found that monitors can be super helpful as well as experienced, at the same they make
the things difficult. Really the quality of monitoring depends on the CRO. I found that
every monitor is a bit different in their requests and style. Some are very easy to work
with, while others are extremely difficult. It’s hard to answer their questions and make
blanket statements. 60 to 70% of the monitors I have worked with are not helpful in
cleaning up our regulatory and subject binders.
The quality has gone down and monitors are responsible for too many protocols. The
communication between CRO, sponsor and site is not good. On an average, we are seeing
new monitors every six months.
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Appendix A: College of Health and Human Services Human Subjects Review
Committee Approval Letter
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Appendix B: Survey Completion Request or Online Survey Consent Form or Email
Survey
Survey Title:
“Perceptions of Clinical Research Coordinators about Quality of Monitoring”
Dear Clinical Research Coordinator:
As a part of my master’s thesis, I am requesting your participation in a survey.
You are being invited to complete this survey about quality of monitoring and
major concerns/failings in the monitoring process from the perspective of clinical
research coordinators. You were selected as a possible participant in my search for
clinical research coordinators in Google and finally, I found your email contact in the
website of the institution or company or clinical trial center that you are working. I
strongly advise you do not use employer issued device (laptop, smart phones etc.) to
respond to this survey. This research project is done by Praveen Krishna Movva from
Eastern Michigan University.
Your participation is voluntary and you may choose not to participate. If you
decide to participate in this research survey, you may withdraw at anytime. Your
participation and responses will be kept anonymous. There are no direct benefits
associated with your participation, but your input is valued. There is no known risk
involved in your participation.
As a researcher I respect your rights to privacy and I hold in the utmost respect
your responses to this survey and I will keep the survey results confidential. I am not
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collecting any kind of personal identifiable information and personal health information
during the course of this survey.
The data will be collected via the online survey (Google Docs) and the results of
the survey will be held by me. I will hold the data on a password protected personal
laptop; there is no access to anyone. I will be protecting the laptop from theft and the
word document containing email list for survey is both encrypted and password
protected. The folder on my laptop (password protected) containing the results of the
survey will be deleted upon the submission of the dissertation and the password protected
document containing email list for survey will be deleted upon the completion of survey.
I will be sending the survey to potential participants by using Google docs and the
survey tool or document or form containing emails will be deleted forever upon the
analysis of results. Privacy Policy of Google
http://www.google.com/intl/en/policies/privacy/
I have taken all reasonable measures to protect your identity and responses.
However, email and the internet are not 100% secure, so it is also suggested that you
clear the browser history to protect your privacy after completing the survey.
The procedure for survey involves answering six demographics questions and
fifteen questions about monitoring practices. The survey takes about 15 to 20 minutes to
complete.
Click on the following link to access the survey:
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https://docs.google.com/spreadsheet/viewform?formkey=dHY4bkNzdGowbTRIVFJ0Tm
JTX3NkZUE6MQ
By clicking on the link above, you are indicating that:
•

You have read above information.

•

You voluntarily agree to participate.

•

You are a clinical research coordinator.
I hope you will respond. This survey will be available for approximately two

weeks to allow your participation.
If you have any questions about the study, please contact Dr. Stephen A. Sonstein,
Professor and Director of Clinical Research Administration, Eastern Michigan
University, ssonstein@emich.edu.
Thank you in advance for your participation!
“This research protocol and informed consent document has been reviewed
and approved by the Eastern Michigan University Human Subjects Review
Committee for use from November 7 2012 to November 6 2013 (date). If you have
questions about the approval process, please contact Dr. Gretchen Dahl Reeves
(734-487-3236, Chair, College of Health and Human Services Human Subjects
Review Committee, greeves@emich.edu).
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Appendix C: Survey
Survey Title:
“Perceptions of Clinical Research Coordinators about Quality of Monitoring”
Survey Questions include six demographic questions and 15 questions related to
monitoring practices.
Demographic Questions:
1. What is the highest degree (or) level of education you have completed?
•

High School Graduate

•

Associate degree

•

Bachelor’s degree

•

Post-baccalaureate certificate

•

Master’s degree

•

Doctorate degree

•

Other(Please Specify)

2. Which of the following best describes your educational background?
•

Nursing degree

•

Life Science degree (e.g. Pharmacy, Biochemistry, Biology)

•

Health Science degree (e.g. Clinical Laboratory Science, Physical
Therapy)

•

Clinical Research degree

•

Other (Please Specify)

3. Which of the following best describes your current work setting?
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•

Private Practice site

•

Academic site (University or Teaching Hospitals)

•

Community Hospital (Not Academically affiliated)

•

Site management organization (organizing a group of sites centrally to do
studies)

•

Contract research organization (company or organization contracted by a
pharmaceutical, medical device or biotechnology company to conduct
clinical trials)

•

Other (please specify)

4. Which of the following describes your current working pattern? (Select all that
apply)
•

Medical device clinical trials

•

Pharmaceutical clinical trials

•

Investigator - initiated clinical trials

•

Government (or) Foundation – sponsored clinical trials

•

Other (please specify)

5. About how long have you been working as a clinical research coordinator?
•

≤ 2 years

•

> 2 to 5 years

•

> 5 to 10 years

•

> 10 years

6. How many clinical trials have you participated in where you have interacted with
a monitor?
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A “monitor” is a professional who evaluates and analyzes clinical data and
coordinates activities to ensure compliance with protocol and overall clinical
objectives. Synonyms of monitor are clinical research monitor, clinical trials
monitor, clinical research associate etc.
•

1 to 5

•

6 to 10

•

11 to 20

•

> 20

Monitoring Practices Questions:
1. In general, how satisfied are you with the skill and competency of the monitors with
whom you have interacted?
•

Very satisfied

•

Satisfied

•

Not sure

•

Dissatisfied

•

Very dissatisfied

2. In general, how satisfied are you with the monitor’s level of understanding of the
protocol and its requirements?
•

Very satisfied

•

Satisfied

•

Not sure

69

•

Dissatisfied

•

Very dissatisfied

3. In general, how satisfied are you with the review of the informed consent process
conducted by the monitors with whom you have interacted?
•

Very satisfied

•

Satisfied

•

Not sure

•

Dissatisfied

•

Very dissatisfied

4. In general, how satisfied are you with the review for protocol deviations conducted by
the monitors with whom you have interacted?
•

Very satisfied

•

Satisfied

•

Not sure

•

Dissatisfied

•

Very dissatisfied

5. In general, how satisfied are you with the review for accuracy and completeness of
CRF entries and source documents against each other conducted by the monitors with
whom you have interacted?
•

Very satisfied

•

Satisfied
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•

Not sure

•

Dissatisfied

•

Very dissatisfied

6. In general, how satisfied are you with the review for reporting of adverse events
conducted by the monitors with whom you have interacted?
•

Very satisfied

•

Satisfied

•

Not sure

•

Dissatisfied

•

Very dissatisfied

7. In general, how satisfied are you with the review for accuracy of drug accountability
records conducted by the monitors with whom you have interacted?
•

Very satisfied

•

Satisfied

•

Not sure

•

Dissatisfied

•

Very dissatisfied

8. In general, how likely are the monitors with whom you have interacted to fail to review
FDA and IRB approvals prior to study initiation?
•

Very Likely

•

Likely
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•

Not sure

•

Unlikely

•

Very Unlikely

9. In general, how likely are the monitors with whom you have interacted to provide
adequate technical support to the site staff about the study?
•

Very Likely

•

Likely

•

Not sure

•

Unlikely

•

Very Unlikely

10. In general, how likely are the monitors with whom you have interacted to help the site
staff in resolving the generated queries?
•

Very Likely

•

Likely

•

Not sure

•

Unlikely

•

Very Unlikely

11. In general, how likely are the monitors with whom you have interacted to provide site
monitoring reports in a short time frame after completing a monitoring visit?
•

Very Likely

•

Likely
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•

Not sure

•

Unlikely

•

Very Unlikely

12. In general, how likely is it that there is an increase in work load following the
completion of a monitoring visit?
•

Very Likely

•

Likely

•

Not sure

•

Unlikely

•

Very Unlikely

13. In general, in a clinical study, how much do you believe the quality of the data at your
site reflects upon the monitors with whom you have interacted?
•

Very much

•

Moderately

•

Not sure

•

Minimally

•

Does not reflect

14. Has your site been audited or inspected in the past three years? If so, has the monitor
been helpful in preparation for the audit or inspection?
•

Very much

•

Moderately
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•

Not sure

•

Minimally

•

Not at all

15. In general, what is your opinion about the quality of monitoring in clinical trials today
as compared to 5-10 years ago?

74

